| 摘要 |
ABSTRACT - 603739 The disclosure relates to the use of (1) a peptide epoxyketone proteasome inhibitor represented by the structural formula shown herein, or a pharmaceutically acceptable salt thereof; and (2) dexamethasone, in combination, for the manufacture of a medicament for the treatment of multiple myeloma; wherein the medicament is formulated for administration of the peptide epoxyketone proteasome inhibitor and the dexamethasone within about 5 minutes to within about 48 hours of one another; and wherein the efficacy shown by administering (1) and (2) in combination is greater than the efficacy shown by administering either of (1) or (2) alone; and wherein the medicament may further comprises lenalidomide. |
